Clinical trials: APL, open to volunteers
APL
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia
Based on the current treatment with retinoic acid (ATRA) and arsenic (As), most patients with APL achieved long-term survival. There are few patients relapsed and became refractory to the RA and As treatment.
- Trial name
- NCT05881265
- Testing
- Chidamide+venetoclax
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia
A Trial to Investigate Whether Oral Arsenic Trioxide Is Similar to Intravenous Arsenic Trioxide in Pharmacokinetics, Safety, and Efficacy (LATITUDE/SDKARS-301)
LATITUDE: A Phase 3, Randomized, Open-Label, 3-Cohort, 2-Period, 2- Sequence, Crossover Trial to Evaluate the Pharmacokinetics, Safety, and Efficacy of Oral Arsenic Trioxide Versus Intravenous Arsenic Trioxide for Consolidation…
- Conditions
- Acute Promyelocytic Leukemia (APL), Acute Promyelocytic Leukaemia, Acute Promyelocytic Leukemia With PML-RARA, Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Trial name
- LATITUDE (NCT07296445)
- Testing
- Oral ATO, IV Arsenic Trioxide, all-trans retinoic acid (ATRA)
- Volunteers
- 120 people
- Sponsor
- SDK Therapeutics, Inc.
Acute Promyelocytic Leukemia With PML-RARA
Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
This phase II trial studies how well tretinoin and arsenic trioxide with or without gemtuzumab ozogamicin works in treating patients with previously untreated acute promyelocytic leukemia.
- Trial name
- NCT01409161
- Testing
- Arsenic Trioxide, Gemtuzumab Ozogamicin, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 151 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Promyelocytic Leukemia (APL)
Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
This study is to assess the efficacy and safety of Lisaftoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
- Trial name
- NCT07597941
- Testing
- Lisaftoclax (APG-2575)
- Volunteers
- 20 people
- Sponsor
- The Affiliated People's Hospital of Ningbo University
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
The primary objective of this multicenter observational registry is to characterize the clinical, epidemiological, and biological profiles of individuals of Middle Eastern, North African, and Levantine ancestry, including…
- Conditions
- Antiphospholipid (aPL)-Positive, Rheumatic Arthritis, Celiac Disease, Focal Segmental Glomerulosclerosis (FSGS)
- Trial name
- MERIT (NCT07892651)
- Where
- Jordan
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Axiom Bioregistry
Acute Promyelocytic Leukemia
Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia
The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who are PCR-positive for the PML-RARα transcript and less than 18 years of age.
- Trial name
- NCT04793919
- Testing
- Mylotarg, Arsenic Trioxide, All-trans retinoic acid
- Where
- 31 sites in Belgium, Czechia and 10 more
- Volunteers
- 89 people
- Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
Acute Promyelocytic Leukemia
Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients
This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.
- Trial name
- Ven APL (NCT06544109)
- Testing
- venetoclax
- Where
- China
- Volunteers
- 98 people
- Sponsor
- The First Affiliated Hospital of Soochow University